Labcorp Perspectives: Oncology | How can HRD testing help patients with ovarian cancer? (Episode 2)

Presented by:

Dr. Rebecca Previs, MD, Director of Medical Affairs at Labcorp

Dr. Alison Roos, PhD, Associate Director of Medical Affairs at Illumina

Molecular Tumor Board: 54-year-old male with accelerated phase CML and ABL1 T315I mutation

Molecular Tumor Board: 77-year-old female with metastatic breast cancer with PIK3CA H1047R mutation and 83-year-old female with metastatic breast cancer with AKT1 L52R mutation

Dr. Marcela Mazo Canola, Assistant Professor of Medicine, Breast Medical Oncology at UT Health San Antonio Mays Cancer Center joined our Oncology Medical Affairs Directors, Kyle Strickland and Heidi Ko to discuss the importance of biomarker testing for therapeutic implications in metastatic breast cancer. Two cases of metastatic hormone receptor-positive, HER2-negative breast cancer with PIK3CA and AKT1 alterations were discussed.

Labcorp Perspectives - Oncology: Understanding an inflamed tumor microenvironment and how to leverage it for targeted therapy(Episode 1)

Molecular Tumor Board: 71-year-old female with intrahepatic cholangiocarcinoma and IDH1 R132C mutation

In this molecular tumor board, our Oncology Medical Affairs Team presents a case of a 71-year-old female with intrahepatic cholangiocarcinoma whose tumor harbors an IDH1 R132C mutation. Watch as they discuss options for targeted therapy, side effects, and the biologic rationale.

Molecular Tumor Board: 44-year-old male with advanced NSCLC and ROS1 fusion

This Molecular Tumor Board, our Oncology Medical Affairs team reviews concurrent tissue- and plasma-based comprehensive NGS testing for the management of a young patient with advanced stage NSCLC. A growing number of guideline-recommended biomarkers are reviewed for frontline targeted therapy selection and prevalence of oncogenic driver alterations in NSCLC. The process of utilizing and optimizing cytology specimens for NGS analysis is also discussed.

Implementing liquid biopsy testing in a routine lab

Molecular Tumor Board: 67-year-old male with HER2-positive, PD-L1 positive advanced gastric adenocarcinoma and 70-year-old male with HER2-negative, PD-L1 negative metastatic gastric adenocarcinoma

What is the current and future state of biomarker testing in gastric cancer?

Find out in this molecular tumor board where we present two cases of advanced stage gastric cancer with contrasting molecular features. We reviewed current and emerging predictive biomarkers of HER2, PD-L1 and CLDN18.2 to guide therapy selection in gastric cancer. We also discussed best practices for tissue acquisition, processing, and handling to maximize the likelihood of successful genomic testing in oncology.

Molecular Tumor Board: 56-year-old male with metastatic ductal adenocarcinoma of pancreas and RET fusion

This molecular tumor board reviews tumor-agnostic biomarker testing and targeted therapy selection for RET alterations in a patient with advanced pancreatic ductal adenocarcinoma. We also provide an overview of risk factors, prognosis and biomarker-driven therapy selection underscoring the importance of comprehensive genomic profiling in patients with advanced pancreatic cancer. 

Molecular Tumor Board: 68 year-old female with Stage IV lung adenocarcinoma and EGFR and KRAS mutations on liquid biopsy

This latest molecular tumor board reviews a case of a 68 year-old female with metastatic lung adenocarcinoma with an EGFR L848R mutation. Frontline biomarker testing provided initial options for therapy, but at progression liquid biopsy testing was confounded by clonal hematopoiesis.